Holen Sie sich die Stockscreener-App
1.52
1.94%
-0.03
Schlusskurs vom Vortag:
$1.55
Offen:
$1.53
24-Stunden-Volumen:
12,083
Relative Volume:
0.14
Marktkapitalisierung:
$54.10M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-14.47M
KGV:
-1.2258
EPS:
-1.24
Netto-Cashflow:
$-12.19M
1W Leistung:
-2.56%
1M Leistung:
-1.94%
6M Leistung:
-41.43%
1J Leistung:
-33.04%
1-Tages-Spanne:
$1.51
$1.55
1-Wochen-Bereich:
$1.49
$1.7618
52-Wochen-Spanne:
$1.45
$3.48
Heartbeam Inc Stock (BEAT) Company Profile
Firmenname
Heartbeam Inc
Sektor
Branche
Telefon
408-899-4443
Adresse
2118 WALSH AVE., SUITE 210, SANTA CLARA
Vergleichen Sie BEAT mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BEAT
Heartbeam Inc
|
1.5261 | 54.10M | 0 | -14.47M | -12.19M | -1.24 |
|
VEEV
Veeva Systems Inc
|
281.56 | 46.43B | 2.86B | 780.66M | 1.20B | 4.72 |
|
TEM
Tempus Ai Inc
|
69.73 | 12.01B | 803.32M | -709.10M | -212.68M | -7.8003 |
|
DOCS
Doximity Inc
|
58.11 | 11.00B | 550.17M | 201.35M | 232.07M | 1.00 |
|
HQY
Healthequity Inc
|
101.28 | 9.27B | 1.15B | 96.70M | -161.99M | 1.09 |
|
WAY
Waystar Holding Corp
|
38.28 | 7.03B | 906.14M | -52.62M | 89.62M | -0.3621 |
Heartbeam Inc Stock (BEAT) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2020-09-11 | Eingeleitet | Needham | Buy |
| 2020-09-02 | Eingeleitet | Robert W. Baird | Neutral |
| 2020-01-08 | Eingeleitet | SunTrust | Buy |
| 2019-08-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2019-04-26 | Bestätigt | Dougherty & Company | Buy |
| 2018-07-26 | Bestätigt | Lake Street | Buy |
| 2018-04-26 | Bestätigt | The Benchmark Company | Buy |
| 2018-02-23 | Bestätigt | Dougherty & Company | Buy |
| 2017-11-08 | Bestätigt | Dougherty & Company | Buy |
| 2017-10-26 | Eingeleitet | Raymond James | Outperform |
| 2017-10-24 | Eingeleitet | SunTrust | Buy |
| 2017-08-09 | Bestätigt | Dougherty & Company | Buy |
| 2017-07-19 | Bestätigt | The Benchmark Company | Buy |
| 2017-04-11 | Bestätigt | Dougherty & Company | Buy |
| 2016-12-02 | Eingeleitet | Dougherty & Company | Buy |
| 2016-09-13 | Eingeleitet | Sidoti | Buy |
| 2016-08-03 | Bestätigt | The Benchmark Company | Buy |
| 2015-07-28 | Bestätigt | Dougherty & Company | Buy |
| 2013-10-24 | Eingeleitet | The Benchmark Company | Buy |
| 2013-08-21 | Eingeleitet | Dougherty & Company | Buy |
Alle ansehen
Heartbeam Inc Aktie (BEAT) Neueste Nachrichten
IBN Coverage: HeartBeam (NASDAQ: BEAT) Is One to Watch - Yahoo Finance
HeartBeam to Present at the iAccess Alpha Virtual Best Ideas Summer Conference on June 24, 2025 - Business Wire
BEAT Stock: A Comprehensive Analysis and Forecast - investchronicle.com
HeartBeam Inc. Pioneers Cable-Free 12-Lead ECG System for At-Home Cardiac Monitoring - citybuzz -
HeartBeam Inc.'s VALID-ECG Study Confirms High Diagnostic Accuracy of Synthesized 12-Lead ECG - citybuzz -
HeartBeam (NASDAQ: BEAT) VALID-ECG Study Confirms Diagnostic Accuracy of Synthesized 12-Lead ECG - financial-news.co.uk
HeartBeam Inc. Advances Toward Commercialization with Promising Q1 2025 Results - citybuzz -
Here's Why HeartBeam (NASDAQ:BEAT) Must Use Its Cash Wisely - Yahoo Finance
HeartBeam CEO Named to Company’s Board of Directors - Medical Product Outsourcing
Benchmark maintains $8 target on Heartbeam stock post-1Q report - Investing.com Australia
Benchmark maintains $8 target on Heartbeam stock post-1Q report By Investing.com - Investing.com India
HeartBeam’s Positive Earnings Call Reflects Growth Potential - TipRanks
HeartBeam, Inc. (NASDAQ:BEAT) Q1 2025 Earnings Call Transcript - Insider Monkey
HeartBeam (NASDAQ: BEAT) Hits FDA Milestone and Expands Strategic Partnerships in Q1 Update - Barchart.com
HeartBeam (BEAT) Reports Advancements in Q1 2025 | BEAT Stock Ne - GuruFocus
HeartBeam reports net loss of USD 5.5M in Q1 2025 - Medical Buyer
HeartBeam, Inc. Reports Q1 2025 Financial Results - TipRanks
Earnings call transcript: HeartBeam Q1 2025 miss doesn’t deter investors By Investing.com - Investing.com South Africa
Heartbeam Inc reports results for the quarter ended March 31Earnings Summary - TradingView
HeartBeam Q1 2025 slides: FDA progress and commercial readiness amid continued losses - Investing.com Nigeria
HeartBeam, Inc. SEC 10-Q Report - TradingView
HeartBeam Reports First Quarter 2025 Results - Business Wire
The Week in Canadian Press Releases: 10 Stories You Need to See - The Globe and Mail
HeartBeam strengthens IP with US patents for cardiac monitoring - Yahoo Finance
Two New U.S. Patents Bring Total to 20 Issued Worldwide, - openPR.com
Two New U.S. Patents Bring Total to 20 Issued Worldwide, Cementing Company Leadership in Cardiac Monitoring Innovation for 12-Lead ECG Synthesis Technology: HeartBeam, Inc. (Nasdaq: BEAT) - Barchart.com
HeartBeam Secures 2 New U.S. Patents - Medical Product Outsourcing
HeartBeam (NASDAQ: BEAT) Adds Two U.S. Patents to Bolster Cardiac Monitoring IP Portfolio - Barchart.com
HeartBeam (BEAT) Expands IP Portfolio with New U.S. Patents | BEAT Stock News - GuruFocus
HeartBeam Announces Two New U.S. Patents, Powering Forward Its Robust Patent Portfolio - Business Wire
HeartBeam Expands Board with CEO Robert Eno’s Appointment - citybuzz -
HeartBeam (NASDAQ: BEAT) Appoints CEO Robert Eno To Board Of Directors - Barchart.com
HeartBeam (BEAT) Welcomes CEO Robert Eno to Its Board of Directo - GuruFocus
HeartBeam Appoints CEO Robert Eno to Board - TipRanks
HeartBeam expands board, appoints CEO to director role By Investing.com - Investing.com India
HeartBeam expands board, appoints CEO to director role - Investing.com Australia
HeartBeam Appoints CEO Robert Eno to Board of Directors to Support U.S. Commercialization and Growth - Bluefield Daily Telegraph
HeartBeam, Inc. Appoints Robert Eno to Board of Directors - marketscreener.com
HeartBeam (NASDAQ: BEAT) Prices $10 Million Public Offering At $1.70 Per Share - Barchart.com
HeartBeam (NASDAQ: BEAT) to Report Q1 2025 Results and Provide Business Update on May 13 - Barchart.com
HeartBeam to Host First Quarter 2025 Results Conference Call on Tuesday, May 13, 2025 at 4:30 p.m. Eastern Time - Bluefield Daily Telegraph
HeartBeam’s ECG technology shows promise in study for arrhythmia diagnosis - Yahoo Finance
HeartBeam Successfully Meets Clinical Endpoints in Pivotal Study for its Groundbreaking 12-Lead ECG Synthesis Technology - BioSpace
Strategic Collaboration with AccurKardia for Ambulatory ECG - openPR.com
Strategic Collaboration with AccurKardia for Ambulatory ECG Recording and Analysis to Advance Cardiac Monitoring Care: HeartBeam, Inc. (Nasdaq: BEAT) - The Globe and Mail
Strategic Collaboration with AccurKardia for Ambulatory ECG Recording and Analysis to Advance Cardiac Monitoring Care: HeartBeam, Inc. (Nasdaq: BEAT) | FinancialContent - FinancialContent
HeartBeam (NASDAQ: BEAT) Reports Positive VALID-ECG Study Results Supporting 12-Lead ECG Tech - Barchart.com
HeartBeam’s VALID-ECG Study of 12-Lead ECG Synthesis Tech Meets Endpoints - Medical Product Outsourcing
Finanzdaten der Heartbeam Inc-Aktie (BEAT)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.48%
1.84%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):